查詢結果分析
相關文獻
- Triple Therapy with Hydroxychloroquine, Azithromycin, and Ciclesonide for COVID-19 Pneumonia
- Triple Therapy with Hydroxychloroquine, Azithromycin, and Ciclesonide for COVID-19 Pneumonia
- Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in Treating COVID-19 Patients
- The Precaution Strategy toward the COVID-19 Pandemic in the Operating Room of a Tertiary Hospital in Taiwan
- Highlight of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Development against COVID-19 Pandemic
- Clinical Validation of an Automated Reverse Transcription-insulated Isothermal PCR Assay for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2
- Need for a High-specificity Test for Confirming Weakly Positive Result in an Immunochromatographic SARS-CoV-2-specific Antigen Test: A Case Report
- Taiwan's COVID-19 Response: Timely Case Detection and Quarantine, January to June 2020
- Initial SARS-CoV-2 PCR Crossing Point Does Not Predict Hospitalization and Duration of PCR Positivity、
- Initial SARS-CoV-2 PCR Crossing Point Does Not Predict Hospitalization and Duration of PCR Positivity、
頁籤選單縮合
題 名 | Triple Therapy with Hydroxychloroquine, Azithromycin, and Ciclesonide for COVID-19 Pneumonia |
---|---|
作 者 | Mori, Nobuaki; Katayama, Mitsuya; Nukaga, Shigenari; | 書刊名 | Journal of Microbiology, Immunology and Infection |
卷 期 | 54:1 2021.02[民110.02] |
頁 次 | 頁109-112 |
分類號 | 412.471 |
關鍵詞 | COVID-19; SARS-CoV-2; Pneumonia; Hydroxychloroquine; Azithromycin; Ciclesonide; Therapy; Reverse transcription-PCR; |
語 文 | 英文(English) |